PP03A
Metabolic disease – ultra‑long‑acting GLP‑1 receptor agonist
PreclinicalActive
Key Facts
Indication
Metabolic disease – ultra‑long‑acting GLP‑1 receptor agonist
Phase
Preclinical
Status
Active
Company
About PolyPid
PolyPid delivers precision, long‑acting drug depots via its Kynatrix™ platform to improve outcomes in surgery, metabolism and cancer.
View full company profile